Skip to main content
Press Releases

Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS

By November 10, 2016No Comments

Data Will Highlight the Potential Broad Clinical Utility and
Subcutaneous Administration of CD101 for Invasive Fungal Infections

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical and clinical studies evaluating its
novel echinocandin antifungal CD101 as a potential treatment for
invasive fungal infections will be presented at the joint conference of
the International Immunocompromised Host Society (ICHS) and INFOCUS
Latinomérica from November 13-15, 2016 in Santiago, Chile. CD101 is
Cidara’s lead antifungal drug candidate and the only long-acting
antifungal in the echinocandin class.

The ICHS and INFOCUS are prestigious annual events highlighting the
latest developments related to infections in immunocompromised patients
and fungal infections, respectively. They are hosting their meetings
together for the first time to address the increasing incidence of
fungal infections in immunocompromised patients.

CD101 data being presented at the joint ICHS/INFOCUS conference will
include new results from preclinical studies evaluating subcutaneous
administration of the compound, which represents a novel approach in
antifungal treatment and prevention. This abstract was selected by the
conference’s Scientific Committee as one of the top works of all that
were submitted, a recognition that reflects the importance of and
interest in this research. A second presentation will review data from
two recently completed Phase 1 dose-escalation trials of CD101 IV that
demonstrate the compound’s clinical pharmacokinetics, safety and
tolerability. CD101 IV is currently being developed as a once-weekly
treatment for invasive fungal infections.

“Cidara’s presence at this international forum demonstrates our
commitment to broadening the dissemination of our scientific work in
novel antifungal drug development and advancing new treatment options to
support immunocompromised patients, who are at high risk of developing
life-threatening fungal infections,” said Jeffrey Stein, Ph.D.,
president and chief executive officer of Cidara. “We look forward to
engaging with this scientific community to share the latest results of
our CD101 clinical research, including the exciting study investigating
the potential to broaden utility for CD101 through availability of a
subcutaneous injection.”

Titles and abstract numbers for the Cidara ICHS/INFOCUS poster
presentations are as follows:

  • 048: Subcutaneous (SC) Injection of
    CD101, a Novel Echinocandin: Efficacious, Well-Tolerated and Sustained
    Drug Exposures; V. Ong, et. al.
  • 065: Safety and Pharmacokinetics of
    Single and Multiple Doses of CD101 IV: Results from Two Phase 1
    Dose-Escalation Studies; T. Sandison, et. al.

Posters will be on display beginning Monday, November 14, 2016 at 10:00
a.m. through Tuesday, November 15, 2016 at 5:00 p.m., CLST. There are
also two poster viewing times on Monday and Tuesday from 4:00 p.m. to
5:00 p.m., CLST.

Copies of these posters will be available on the Cidara website
following the meeting:

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101, through Phase 2
studies in two indications and developing CD201, its bispecific
antimicrobial immunotherapy, for the treatment of multi-drug resistant
bacterial infections. CD101 IV has enhanced potency and is the only
once-weekly therapy intended for the treatment and prevention of
life-threatening invasive fungal infections. CD101 topical is the first
and only agent of its class being studied for the treatment and
prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal
infection. CD201 is the first drug candidate selected from Cidara’s
novel Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient’s immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara is headquartered in San Diego, California. For more information,
please visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
subcutaneous, and their potential to treat infections. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in the United States and
foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were

Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director

Sam Brown Inc.
Christy Curran, 615-414-8668